Flow Cytometry Evaluated for Cord Blood Differentials
|
By LabMedica International staff writers Posted on 20 Feb 2013 |
The potential of flow cytometry to analyze and to report leukocyte differentials on cord blood to be used for hematopoietic stem cells has been evaluated.
Currently, the reference method for white blood cell (WBC) is the microscopic manual count, but international standards advise that potential donor blood is tested for total nucleated cell count, nucleated red blood cell count (nRBCs), total number of CD34 cells, viability or potency as measured by viable CD34 cells. Colony-forming unit assays, microbial cultures, and finally a complete blood count with WBC differential are also advisable.
Hematologists at the Centre Hospitalier Universitaire (CHU; Rennes, France) analyzed 161 cord bloods between November 2010 and February 2011. WBC differentials were determined for each sample, by a cell counter, a manual method, and the flow cytometry using an antibody cocktail. WBC differential includes the count of neutrophils, eosinophils, basophils, lymphocytes, monocytes, immature granulocytes, and blasts cells.
All samples were analyzed on the HematoFlow platform (Beckman Coulter, Miami, FL, USA) within 12 hours of collection. This platform is built around Beckman Coulter's FP1000 cell preparator, along with their FC500 five-color flow cytometer. The antibody cocktail used was another Beckman Coulter product called the CytoDiff.
A good correlation was obtained for neutrophils, lymphocytes, and immature granulocytes when the manual method was compared to the flow cytometry, but was weaker for eosinophils and even lower for monocytes and basophils. The flow cytometry method employed allowed the identification of 12 cell
subtypes (neutrophils, eosinophils, basophils, B lymphocytes, T-non-cytotoxic and T cytotoxic/Natural Killer (NK) lymphocytes, CD16 negative monocytes and CD16 positive monocytes, immature granulocytes, B blasts, T blasts and non-B-non-T blasts) within a single panel of antibodies and a minimal volume of 50 µL of blood.
The authors concluded that the flow differential has some drawbacks such as the cost of CytoDiff reagent, but this can be balanced by the reduction in technician time required for manual counting and the use of a standardized product. The flow cytometry appears as a technique completely adapted to provide a WBC differential on a cord blood sample. The additional cell subset counts offered in the same turn-around-time would probably be exploited in the near future to better characterize the engraftment potential. The study was published in the February 2013 issue of the International Journal of Laboratory Hematology.
Related Links:
Centre Hospitalier Universitaire
Beckman Coulter
Currently, the reference method for white blood cell (WBC) is the microscopic manual count, but international standards advise that potential donor blood is tested for total nucleated cell count, nucleated red blood cell count (nRBCs), total number of CD34 cells, viability or potency as measured by viable CD34 cells. Colony-forming unit assays, microbial cultures, and finally a complete blood count with WBC differential are also advisable.
Hematologists at the Centre Hospitalier Universitaire (CHU; Rennes, France) analyzed 161 cord bloods between November 2010 and February 2011. WBC differentials were determined for each sample, by a cell counter, a manual method, and the flow cytometry using an antibody cocktail. WBC differential includes the count of neutrophils, eosinophils, basophils, lymphocytes, monocytes, immature granulocytes, and blasts cells.
All samples were analyzed on the HematoFlow platform (Beckman Coulter, Miami, FL, USA) within 12 hours of collection. This platform is built around Beckman Coulter's FP1000 cell preparator, along with their FC500 five-color flow cytometer. The antibody cocktail used was another Beckman Coulter product called the CytoDiff.
A good correlation was obtained for neutrophils, lymphocytes, and immature granulocytes when the manual method was compared to the flow cytometry, but was weaker for eosinophils and even lower for monocytes and basophils. The flow cytometry method employed allowed the identification of 12 cell
subtypes (neutrophils, eosinophils, basophils, B lymphocytes, T-non-cytotoxic and T cytotoxic/Natural Killer (NK) lymphocytes, CD16 negative monocytes and CD16 positive monocytes, immature granulocytes, B blasts, T blasts and non-B-non-T blasts) within a single panel of antibodies and a minimal volume of 50 µL of blood.
The authors concluded that the flow differential has some drawbacks such as the cost of CytoDiff reagent, but this can be balanced by the reduction in technician time required for manual counting and the use of a standardized product. The flow cytometry appears as a technique completely adapted to provide a WBC differential on a cord blood sample. The additional cell subset counts offered in the same turn-around-time would probably be exploited in the near future to better characterize the engraftment potential. The study was published in the February 2013 issue of the International Journal of Laboratory Hematology.
Related Links:
Centre Hospitalier Universitaire
Beckman Coulter
Latest Hematology News
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








